

9. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. *Am Heart J*. 1993;125:1148-1154.
10. Pittaras A, Kokkinos P, Faselis Ch, et al. Resting heart rate and mortality risk in hypertensive patients with no atrial fibrillation. *Journal of Hypertension*. 2024;42:e-Supplement 1, e50.
11. Wen ChP, Chen ChH, Nauman J, et al. Resting heart rate – The forgotten risk factor? Comparison of resting heart rate and hypertension as predictors of all-cause mortality in 692,217 adults in Asia and Europe. *Progress in cardiovascular diseases*. 2025;89:25-44.
12. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. *Am Heart J*. 1992;123:609-16.
13. Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. *Int J Cardiol*. 2013;168:1490-1495.
14. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension*. 2005;45:240-245.
15. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *J Am Med Assoc*. 1999;282:539-546.
16. Fagard RH, Celis H, Thijs L, et al. Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension. *Hypertension*. 2008;51:55-61.
17. Palatini P, Reboldi G, Beilin LJ, et al. Masked tachycardia. A predictor of adverse outcome in hypertension. *J Hypertens*. 2017;35:487-492.
18. Eguchi K, Hoshida S, Ishikawa J, et al. Nocturnal non-dipping of heart rate predicts cardiovascular events in hypertensive patients. *Journal of Hypertension*. 2009;27:2265-2270.
19. Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Blunted heart rate dip during sleep and all-cause mortality. *Arch Intern Med*. 2007;167:2116-2121.
20. Byun S, Kim AY, Jang EH, et al. Detection of major depressive disorder from linear and nonlinear heart rate variability features during mental task protocol. *Comput Biol Med*. 2019;112:103381.
21. Mancia G, Kreutz R, Brunström M., et al. 2023 ESH guidelines for the management of arterial hypertension. *J Hypertens*. 2023;41:1874-2071.
22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ASH guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(33):3021-3104.
23. Johansen CD, Olsen RH, Pedersen LR, et al. Resting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. *Eur Heart J*. 2013;34:1732-1739.
24. Palatini P, Palomba D, Bertolo O, et al. The white-coat effect is unrelated to the difference between clinic and daytime blood pressure and is associated with greater reactivity to public speaking. *J Hypertens*. 2003;21:545-553.
25. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. *Am Heart J*. 1991;121:172-177.
26. Gianaros PJ, Sheu LK. A brain phenotype for stressor-evoked blood pressure reactivity. *J Am Heart Assoc*. 2017;6:e006053.
27. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? *Nat Rev Cardiol*. 2011;8:369-379.
28. Custodis F, Schirmer SH, Baumhäkel M, et al. Vascular pathophysiology in response to increased heart rate. *J Am Coll Cardiol*. 2010;56:1973-83.
29. Palatini P, Julius S. Heart rate and the cardiovascular risk. *J Hypertens*. 1997;15:3-17.
30. Poirier L, Tobe S. W. Contemporary use of β -blockers: clinical relevance of subclassification. *Can J Cardiol*. 2014;30(5) Suppl.: S9–S15.
31. De la Sierra A, Gorostidi M, Banegas JR, et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. *J Clin Hypertens*. 2015;17(11):857-865.
32. Říháček I, Souček M, Fráň P. Betablokátory v léčbě kardiovaskulárních onemocnění. *Medicina pro praxi*. 2005;2:58-61.
33. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*. 2009 Mar;122(3):290-300.
34. Hradec J. Je nám jasné postavení ivabradinu? *Interní Med*. 2013;15(8-9):273-276.
35. Blanck P, Stoffel M, Bents H, et al. Heart Rate Variability in Individual Psychotherapy Associations With Alliance and Outcome. *J Nerv Ment Dis*. 2019;207:451-458.
36. Tylš F. Ketaminem asistovaná psychoterapie v klinické praxi. *Psychiatrie*. 2025;29:15-22.
37. Frishman WH. Beta-adrenergic blockers: a 50-year historical perspective. *Am J Ther*. 2008;15(6):565-576.

Odborné informace pro vaši praxi – nyní i na Instagramu!



SOLEN MEDICAL EDUCATION

- Zajímavosti z odborných akcí
- Odemčené články
- Klinické kvízy napříč obory
- Soutěže o předplatné a registrace na kongresy
- Propojení s komunitou mladých i zkušených lékařů

Sledujte nás na @solen_cz a nechte si předepsat medicínu, která vás baví: přehledně, pravidelně a s respektem k vaší odbornosti.